- Report
- April 2025
- 120 Pages
Global
From €5318EUR$5,950USD£4,635GBP
- Report
- March 2025
- 200 Pages
Global
From €2225EUR$2,490USD£1,940GBP
- Report
- May 2025
- 200 Pages
Global
From €2225EUR$2,490USD£1,940GBP
- Report
- July 2025
- 100 Pages
Global
From €4379EUR$4,900USD£3,817GBP
From €4379EUR$4,900USD£3,817GBP
- Report
- July 2025
- 175 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- April 2025
- 175 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- February 2025
- 200 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- January 2025
- 175 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- June 2025
- 150 Pages
Global
From €3441EUR$3,850USD£2,999GBP
€4335EUR$4,850USD£3,778GBP
- Report
- July 2025
- 175 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- April 2025
- 175 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- April 2025
- 250 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- April 2025
- 200 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- February 2025
- 200 Pages
Global
From €4013EUR$4,490USD£3,498GBP
- Report
- April 2025
- 192 Pages
Global
From €4022EUR$4,500USD£3,506GBP
- Report
- April 2025
- 197 Pages
Global
From €4022EUR$4,500USD£3,506GBP
- Report
- August 2025
- 220 Pages
Global
From €5228EUR$5,850USD£4,557GBP
- Report
- August 2025
- 178 Pages
Global
From €5228EUR$5,850USD£4,557GBP
- Report
- August 2025
- 282 Pages
Global
From €5228EUR$5,850USD£4,557GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more